Partner with us
Our innovative finance products support partnerships that increase access to medical innovations for people around the world.
We help manufacturers improve access to their products
Our goal is for more people to access medical innovations that can protect their lives and improve their health.
We recognise that manufacturers are cautious about entering or scaling up in low- and middle-income countries.
Our financial products provide assurance and incentives for companies to invest in making their health products available at scale and at prices countries, procurers and patients can afford.
For more information, please get in touch with us today.
Savings for procurers
Our agreements are resulting in procurement savings for governments, donors, and public bodies, leading to increased access to products that otherwise wouldn’t be available in these countries.
Our volume guarantees enable businesses to get medical innovations into the hands of people who need them most and lead to new viable market conditions for sustainable procurement and supply.
For example, to increase access to viral load testing via Hologic’s Panther platform, which provides viral load testing for HIV, viral hepatitis and COVID-19, our guarantee set a per patient test ceiling price of $12 and was also the first all-inclusive price, covering other essentials such as installation, reagents, and maintenance.
The products we support
Our agreements help to increase access to a wide range of medical innovations. To date, we have supported access to vaccines, therapeutics, and diagnostics, as well as essential supplies, such as syringes and clinical equipment, to tackle COVID-19.
We support products that are ready for market. They must have successfully completed clinical trials and been approved by a stringent regulatory authority or prequalified by the World Health Organization (WHO).
We are not involved in research and development of new products. We recognise that other partners are better placed to support the development of new innovations. MedAccess’ focuses on helping ensure these new innovations reach the people who need them as quickly as possible.
Where we work
Our agreements increase access to medical innovations for people living in low- and middle-income countries that are eligible for official development assistance, as defined by the Organisation for Economic Co-operation and Development (OECD).
At least 50% of patients receiving products as the result of an agreement must be based in priority territories as defined by our sole shareholder, British International Investment. These include territories based in sub-Saharan Africa and South Asia.
Since 2017, our agreements have secured affordable access to medical innovations for 539 million people in over 110 low- and middle-income countries.
Our partnership process
We carefully select partnerships to ensure our agreements have maximum health impact.
Our rigorous process begins with comprehensive needs assessments, followed by scoping and alignment phases to ensure we have the right tools to help.
We conduct thorough diligence of the market and of our potential partners before entering into negotiations on a potential agreement.
When an agreement has been reached, we execute the contract and collaborate closely with partners to support country introductions and help solve any problems.
We closely monitor all our agreements to ensure they achieve their expected impact.
